TXMD TherapeuticsMD, Inc.
Legal ·
TherapeuticsMD (Nasdaq: TXMD) sued Mayne Pharma LLC in Delaware over net working capital allowances and faces a countersuit. Teva and Sun Pharma are defendants in New Jersey patent cases over generic IMVEXXY.
The royalty company reported net income from continuing operations of $103 thousand and cash of $8.4 million as of March 31, 2026, and said it still evaluates strategic alternatives.
TherapeuticsMD filed a Form 12b-25 notice on April 1, 2026 after a printer error left the predecessor auditor's report out of its 2025 annual report. The company reported a 2025 net loss of $569,000 and year-end cash of $7.5 million.
TherapeuticsMD stockholders approved raising authorized common stock to 640,000,000 shares at the December 15, 2025 annual meeting. The company had 11,574,362 shares outstanding at the record date, and the increase drew 548,884 votes against.
TherapeuticsMD, Inc. is a pharmaceutical royalty company that owns or has rights to trademarks such as TherapeuticsMD, vitaMedMD, BocaGreenMD, BIJUVA and IMVEXXY. It was previously a women's healthcare company, and in December 2022 it changed its business to become a royalty company, receiving royalties on products licensed to pharmaceutical organizations with commercial capabilities. Under the Mayne Transaction, which closed on December 30, 2022, Mayne Pharma LLC received an exclusive license to commercialize IMVEXXY, BIJUVA and prescription prenatal vitamins sold under the BocaGreenMD and vitaMedMD brands in the United States. TherapeuticsMD also assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. Mayne Pharma agreed to pay royalties on U.S. net sales of the products, starting at 8.0% on the first $80.0 million in annual net sales, for 20 years after the closing date. It also agreed to pay minimum annual royalties of $3.0 million per year for 12 years, subject to adjustment.
| Product or program | What it is | Stage |
|---|---|---|
| IMVEXXY | Licensed to Mayne Pharma for U.S. commercialization | Licensed to Mayne Pharma (United States) |
| BIJUVA | Licensed to Mayne Pharma for U.S. commercialization | Licensed to Mayne Pharma (United States) |
| ANNOVERA | Exclusive license assigned to Mayne Pharma for U.S. commercialization | Assigned to Mayne Pharma (United States) |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.8 million | |
| Net income (loss) | -$569,000 | -$2.2 million |
| Cash and equivalents | $7.5 million | $5.1 million |
Our latest story on this, dated Aug 11, 2026: "TherapeuticsMD's Mayne Pharma suit is stayed; IMVEXXY patent cases against Teva and Sun continue". The story links the filing or release it is based on. Read the story.
TherapeuticsMD, Inc. trades under the ticker TXMD on NASDAQ.
TherapeuticsMD, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:29TA.
The SEC Central Index Key (CIK) for TherapeuticsMD, Inc. is 25743. Its filings are on SEC EDGAR.
11,574,362 shares as of 2026-08-09, per the cover page of its 10-Q filed 2026-08-11.
Our directory records TherapeuticsMD, Inc. under United States.
Our directory classifies TherapeuticsMD, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for TherapeuticsMD, Inc. is US88338N2062.
aibio.space lists TherapeuticsMD, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
TherapeuticsMD, Inc. is a pharmaceutical royalty company that owns or has rights to trademarks such as TherapeuticsMD, vitaMedMD, BocaGreenMD, BIJUVA and IMVEXXY. It was previously a women's healthcare company, and in December 2022 it changed its business to become a royalty company, receiving royalties on products licensed to pharmaceutical organizations with commercial capabilities.
IMVEXXY: Licensed to Mayne Pharma for U.S. commercialization Stage: Licensed to Mayne Pharma (United States).
BIJUVA: Licensed to Mayne Pharma for U.S. commercialization Stage: Licensed to Mayne Pharma (United States).
TherapeuticsMD, Inc. reported a net loss of $569,000 for the fiscal year ended Dec 31, 2025, per its annual report to the SEC.
$9.2 million in cash at Jun 30, 2026, per its 10-Q.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio